Tris Pharma
Date | Investors | Amount | Round |
---|---|---|---|
$125m | Debt | ||
* | $16.6m | Grant | |
* | N/A | - | |
Total Funding | AUD25.7m |
Related Content
Recent News about Tris Pharma
EditTris Pharma is a pharmaceutical company dedicated to developing and delivering high-quality, patient-friendly therapeutics that address some of the most challenging medical conditions, including ADHD, pain, addiction, and other diseases of the central nervous system (CNS). The company leverages its industry-leading capabilities and innovative, proprietary technologies to create medicines that provide benefits not available from currently approved therapies. Tris Pharma serves patients worldwide, focusing on improving their quality of life through effective and differentiated therapeutic approaches.
The company operates in the pharmaceutical market, targeting both healthcare providers and patients as its primary clients. Tris Pharma's business model revolves around the research, development, and commercialization of its proprietary therapeutic products. Revenue is generated through the sale of approved medicines and potentially through licensing agreements for its investigational compounds.
Keywords: ADHD, pain, addiction, CNS diseases, therapeutics, proprietary technologies, patient-friendly, pharmaceutical, innovation, healthcare.